> ## Content Index > Fetch the complete content index at: https://www.coios.me/llms.txt > Use this file to discover other available public pages before exploring further. # GLP-1/GIP use in US adults rose to 12% by 2025, a third via non-traditional access - URL: https://www.coios.me/glp-1-gip-use-in-us-adults-rose-to-12-by-2025-a-third-via/ - Published: 2026-10-26T13:25:26.000Z - Updated: 2026-10-26T23:09:25.000Z - Description: GLP-1/GIP use rose from 8.2% to 12.0% of US adults in 18 months, led by weight-loss use. - Author: Daniel Ryan - Tags: Behavioural science, Diet, exercise and sleep, Obesity, diabetes and GLP-1, Revisions and new sources, United States, #preprint, #new, #item, #source-2026-10, #score-85 This prospective cohort study measured GLP-1/GIP use in the Understanding America Study, a nationally representative US panel. Three survey waves from March 2024 to October 2025 covered 9,150 adults, 1,274 reporting any use. Weighted prevalence rose from 8.2% to 12.0%, about 32 million adults, with weight-loss use growing from 4.1% to 5.6%. One in three users had non-traditional access, such as no prescription, online prescribers or compounding pharmacies. Among weight-loss users, 41% used compounding, online or foreign pharmacies and 43% lacked drug coverage. Use, indication and access were self-reported, and the comparisons cannot support causal interpretation. *Why it is interesting: About 9 million users obtained these drugs through routes that generate no insurance claims. These users were younger, healthier and more often female than users with conventional prescriptions and pharmacy fills.* Source [medRxiv : the preprint server for health sciences, 24 October 2026](https://doi.org/10.64898/2026.08.28.26361368?ref=coios.me) Paper GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America Study Authors Chaturvedi R, Gracner T, Perez-Arce F, Suen Sc, Jin J, Orriens B et al. DOI 10.64898/2026.08.28.26361368 Type Preprint Design Prospective nationally representative panel (Understanding America Study), three surveillance waves March 2024–October 2025, n=9150 adults, 1274 users, survey-weighted Verdict New finding Driver [Diet, exercise and sleep](https://www.coios.me/d-diet-activity/) Driver [Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/) Driver [Revisions and new sources](https://www.coios.me/d-data-sources/) Abstract — the authors' own words, CC BY ABSTRACT Importance Evidence on GLP-1/GIP therapies is largely derived from trials enrolling selected populations or medical records that miss utilization outside healthcare channels. No nationally representative cohort has characterized real-world uptake, indications, and access. Objective To characterize GLP-1/GIP prevalence, indication, clinical profile, and access. Design Prospective cohort study with three GLP-1/GIP surveillance waves (March 2024, December 2024, October 2025). Setting The Understanding America Study, an address-based, nationally representative panel of approximately 15,000 US adults aged 18+ years initiated in 2014. Participants UAS participants responding to at least one surveillance wave (n=9150). Exposures GLP-1/GIP use status (never vs any use, comprising current and former use), self-reported primary indication (diabetes, weight loss, or other), and access pathway (traditional vs non-traditional). Main Outcomes and Measures Survey-weighted prevalence of GLP-1/GIP use, overall and by indication and access pathway; sociodemographic, cardiometabolic, treatment, and access characteristics; and smartwatch-derived resting heart rate, heart rate variability, maximum activity heart rate, step count, and sleep duration and variability. Results Among n=9150 adults (1274 with any use; 60.9% female; median age 53 years), weighted prevalence increased 46%, from 8.2% (March 2024) to 12.0% (October 2025) representing 32 million. Weight-loss indications grew, reaching nearly half of use (4.1% to 5.6%); diabetes-indicated use was stable (5.3% to 5.4%). Users carried high cardiometabolic burden (obesity, 68.2%; diabetes, 53.6%) but diverged by indication: diabetes-indicated users were older (median, 59 vs 49 years), whereas weight-loss-indicated users were more often female (69.9% vs 51.3%) and healthier. One in three users (\~9 million) had non-traditional access, especially in weight-loss-indicated users, of whom 33% had no conventional prescription; 41% used compounding, online, or foreign pharmacies; and, 43% lacked coverage. Non-traditional users were five times as likely to report an unlisted, likely compounded formulation (19.8% vs 4.1%). All p<0.05. Conclusions and Relevance Real-world GLP-1/GIP use has grown rapidly and diversified substantially in indication, access, and population profile. One in 3 users obtained treatment through nontraditional channels largely invisible to claims data, raising long-term safety, efficacy, and coverage questions. GLIMMER provides a public, nationally representative longitudinal evidence base for future payer and provider decisions. KEY POINTS Question Who is using glucagon-like peptide-1 receptor agonists or glucose-dependent insulinotropic polypeptides (GLP-1/GIP) therapies in the US, how has use changed since 2024, and how are these medications obtained? Findings In this cohort study of 9150 US adults, GLP-1/GIP use rose significantly from 8.2% to 12.0% (March 2024–October 2025), driven by weight loss; those treated for diabetes were a decade older, lower-income, and in poorer health than those treated for weight loss. Overall, 1 in 3 users obtained treatment outside conventional prescribing and dispensing channels. Meaning A large and growing share of GLP-1/GIP exposure occurs outside the channels visible to claims-based surveillance.